S&P 500
5,911.69
-0.0%
-$0.48
DJI
42,270.07
+0.1%
+$54.34
NASDAQ
19,113.77
-0.3%
-$62.11
Bitcoin
103,956.00
+0.4%
+402.03
AAPL
$201.47
+0.8%
+$1.52
AMZN
$205.07
-0.3%
-$0.63
GOOG
$173.06
+0.1%
+$0.10
META
$648.23
+0.5%
+$3.18
MSFT
$460.71
+0.4%
+$2.03
NVDA
$135.22
-2.9%
-$3.97
TSLA
$346.82
-3.2%
-$11.61
Mbx Biosciences (NASDAQ: MBX)
$12.53
(-1.5%)
-$0.19
Price as of May 30, 2025, 3:58 p.m. ET
Mbx Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mbx Biosciences Company Info
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.